Peter Sullivan

Peter Sullivan is a health policy reporter at The Hill. His work primarily focuses on healthcare policy, with a focus on issues related to the Affordable Care Act, pharmaceutical companies, and health disparities. He is known for his balanced reporting, although some bias can be detected in his articles.

Biography:  https://thehill.com/author/peter-sullivan

95%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

88%

Examples:

  • In the article 'Pfizer, BioNTech flu-COVID vaccine enters Phase 3 trial', there is a noticeable bias towards Pfizer and BioNTech as the author does not mention any potential competitors or alternative treatments.
  • In the article 'Racial disparities persist in breast cancer mortality rates', the author seems to favor the Affordable Care Act's impact on reducing racial disparities in breast cancer mortality rates.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

100%

Examples:

No current examples available.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

Pfizer and BioNTech Initiate Phase 3 Trial for Combination COVID-19 and Flu Vaccine

Broke On: Thursday, 26 October 2023 Pfizer and BioNTech have started a Phase 3 trial for a combination COVID-19 and flu vaccine. The vaccine uses mRNA technology and aims to simplify the vaccination process. The trial's announcement has led to mixed reactions in the stock market.

Merck's Efforts in Addressing Triple-Negative Breast Cancer and Racial Disparities

Broke On: Tuesday, 15 February 2022 Triple-negative breast cancer (TNBC) is a particularly aggressive form of the disease that disproportionately affects Black women. Black women are nearly twice as likely to be diagnosed with TNBC compared to their white counterparts. Racial disparities persist in breast cancer mortality rates, with Black women having a 40% higher breast cancer death rate compared to white women. Merck is developing innovative therapies and promoting health equity to address TNBC and the racial disparities in breast cancer mortality rates.